Álex Bataller

1.2k total citations
51 papers, 319 citations indexed

About

Álex Bataller is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Álex Bataller has authored 51 papers receiving a total of 319 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Hematology, 21 papers in Genetics and 14 papers in Oncology. Recurrent topics in Álex Bataller's work include Acute Myeloid Leukemia Research (37 papers), Chronic Myeloid Leukemia Treatments (12 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (12 papers). Álex Bataller is often cited by papers focused on Acute Myeloid Leukemia Research (37 papers), Chronic Myeloid Leukemia Treatments (12 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (12 papers). Álex Bataller collaborates with scholars based in United States, Spain and France. Álex Bataller's co-authors include Guillermo Garcia‐Manero, Guillermo Montalban‐Bravo, Kelly A. Soltysiak, Tapan M. Kadia, Farhad Ravandi, Courtney D. DiNardo, Nicholas J. Short, Hagop M. Kantarjian, Alexandre Bazinet and Naval Daver and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Álex Bataller

42 papers receiving 318 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Álex Bataller United States 10 208 131 93 90 46 51 319
Nicolaus Kroeger Germany 10 259 1.2× 73 0.6× 90 1.0× 98 1.1× 56 1.2× 42 336
Caterina Alati Italy 10 209 1.0× 78 0.6× 107 1.2× 114 1.3× 30 0.7× 29 313
Sanbin Wang China 9 102 0.5× 74 0.6× 49 0.5× 137 1.5× 52 1.1× 31 259
Gabrielle T. Prince United States 9 155 0.7× 82 0.6× 46 0.5× 114 1.3× 80 1.7× 28 263
Hayley Ma United States 7 245 1.2× 201 1.5× 91 1.0× 93 1.0× 60 1.3× 10 415
Shaowei Qiu China 10 184 0.9× 180 1.4× 53 0.6× 71 0.8× 33 0.7× 67 344
Yafang Wu China 11 181 0.9× 168 1.3× 105 1.1× 33 0.4× 54 1.2× 71 370
Evgenii Shumilov Germany 9 178 0.9× 84 0.6× 75 0.8× 104 1.2× 20 0.4× 34 304
Daniel Egan United States 8 127 0.6× 79 0.6× 33 0.4× 123 1.4× 49 1.1× 22 212
Sajad Khazal United States 10 151 0.7× 66 0.5× 39 0.4× 138 1.5× 42 0.9× 33 322

Countries citing papers authored by Álex Bataller

Since Specialization
Citations

This map shows the geographic impact of Álex Bataller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Álex Bataller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Álex Bataller more than expected).

Fields of papers citing papers by Álex Bataller

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Álex Bataller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Álex Bataller. The network helps show where Álex Bataller may publish in the future.

Co-authorship network of co-authors of Álex Bataller

This figure shows the co-authorship network connecting the top 25 collaborators of Álex Bataller. A scholar is included among the top collaborators of Álex Bataller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Álex Bataller. Álex Bataller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
DiNardo, Courtney D., Kelly S. Chien, Danielle Hammond, et al.. (2025). A Phase 2 study of CPX‐351 in combination with venetoclax in patients with newly diagnosed high‐risk acute myeloid leukemia. HemaSphere. 9(10). e70214–e70214.
2.
Issa, Ghayas C., Sheng F. Cai, Álex Bataller, Hagop M. Kantarjian, & Eytan M. Stein. (2025). Combination Strategies with Menin Inhibitors for Acute Leukemia. Blood Cancer Discovery. 6(6). 547–560. 1 indexed citations
3.
Chien, Kelly S., Ziyi Li, Sanam Loghavi, et al.. (2025). Clinicopathologic characteristics and outcomes of patients with clonal hematopoiesis who progress to myeloid neoplasms. Leukemia. 39(5). 1269–1272. 1 indexed citations
4.
Bataller, Álex, Alexandre Bazinet, Gautam Borthakur, et al.. (2024). Phase Ib/II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood. 144(Supplement 1). 4272–4272.
5.
Bataller, Álex, Hagop M. Kantarjian, Alexandre Bazinet, et al.. (2024). Phase II Study of Cladribine with Low Dose Cytarabine and Venetoclax Alternating with Azacytidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia. Blood. 144(Supplement 1). 56–56. 3 indexed citations
6.
Carrillo, Juan Antonio Cabrera, et al.. (2024). Kinematics of mandibular advancement devices (MADs): Why do some MADs move the lower jaw backward during mouth opening?. Bio-Design and Manufacturing. 7(5). 637–650. 1 indexed citations
7.
Bataller, Álex, Francesca Guijarro, Luis Gerardo Rodríguez‐Lobato, et al.. (2024). At-Home Care Program for Acute Myeloid Leukemia Induction Phase in Patients Treated with Venetoclax-Based Low-Intensity Regimens. Cancers. 16(24). 4274–4274. 1 indexed citations
8.
Bataller, Álex, Juan José Rodríguez‐Sevilla, Kelly S. Chien, et al.. (2024). NPM1‐mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage. Cancer. 130(20). 3452–3462.
9.
10.
DiNardo, Courtney D., Kelly S. Chien, Danielle Hammond, et al.. (2024). Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia. Blood. 144(Supplement 1). 1511–1511. 1 indexed citations
11.
Pérez-Amill, Lorena, Álex Bataller, Julio Delgado, et al.. (2023). Advancing CART therapy for acute myeloid leukemia: recent breakthroughs and strategies for future development. Frontiers in Immunology. 14. 1260470–1260470. 13 indexed citations
12.
Pratcorona, Marta, Ana Garrido, Álex Bataller, et al.. (2023). Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort. Blood Cancer Journal. 13(1). 69–69. 9 indexed citations
13.
Bataller, Álex, Alexandre Bazinet, Courtney D. DiNardo, et al.. (2023). Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Advances. 8(4). 927–935. 36 indexed citations
14.
Bataller, Álex, Guillermo Garcia‐Manero, Abhishek Maiti, et al.. (2023). Fludarabine, Cytarabine (ARA-C) and Pegylated Erwinase (PEGCRISANTASPASE) in Patients with Relapsed or Refractory Leukemia. Blood. 142(Supplement 1). 5971–5971. 1 indexed citations
15.
Pomares, Helena, Francesca Guijarro, Mònica López‐Guerra, et al.. (2023). Characteristics and long‐term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic. British Journal of Haematology. 204(3). 892–897. 3 indexed citations
16.
17.
López‐Guerra, Mònica, Álex Bataller, Francesca Guijarro, et al.. (2022). Real-World Data on Chronic Myelomonocytic Leukemia: Clinical and Molecular Characteristics, Treatment, Emerging Drugs, and Patient Outcomes. Cancers. 14(17). 4107–4107. 9 indexed citations
18.
Bataller, Álex, Ana Garrido, Montserrat Hoyos, et al.. (2021). Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Blood Advances. 6(3). 882–890. 19 indexed citations
19.
Guardia, Rafael Díaz de la, Talía Velasco-Hernández, Francisco Gutiérrez‐Agüera, et al.. (2021). Engraftment characterization of risk-stratified AML in NSGS mice. Blood Advances. 5(23). 4842–4854. 9 indexed citations
20.
Mozas, Pablo, Marc Sorigué, Alfredo Rivas‐Delgado, et al.. (2020). The interval between frontline treatment and the second relapse (PFS2) predicts survival from the second relapse in follicular lymphoma patients. European Journal Of Haematology. 106(3). 428–432. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicolaus Kroeger Breakdown of academic impact, for papers by Caterina Alati Breakdown of academic impact, for papers by Sanbin Wang Breakdown of academic impact, for papers by Gabrielle T. Prince Breakdown of academic impact, for papers by Hayley Ma Breakdown of academic impact, for papers by Shaowei Qiu Breakdown of academic impact, for papers by Yafang Wu Breakdown of academic impact, for papers by Evgenii Shumilov Breakdown of academic impact, for papers by Daniel Egan Breakdown of academic impact, for papers by Sajad Khazal
Rankless by CCL
2026